トラスツズマブ・バイオシミラーの世界市場レポート 2025年

トラスツズマブ・バイオシミラー市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR28.3％で146億9,000万米ドルに成長します。予測期間の成長は、市場競争の激化、バイオシミラー・パイプラインの開発、規制当局の承認と標準化、世界市場への浸透、医師の採用と処方パターンに起因すると考えられます。予測期間の主な動向には、アクセス改善、市場セグメンテーション戦略、教育キャンペーン、バイオシミラーに対する患者の嗜好、医師の受容などが含まれます。

トラスツズマブ・バイオシミラー市場の成長は、乳がんおよび胃がんの有病率の増加の影響を受けています。トラスツズマブのバイオシミラーは、ヒト上皮成長因子受容体2（HER2）が過剰発現している乳がんや転移性胃がんの治療に採用されています。例えば、2023年9月、米国がん学会は、女性において浸潤性乳がんが新たに約297,790例診断され、同年に約4万3,700人の女性が乳がんで死亡すると報告しています。乳がんはインドで流行しているがんの一種で、女性のがんの14％を占めています。このような乳がんや胃がんの有病率の増加は、高価な医薬品と比較して費用対効果が高いため、トラスツズマブ・バイオシミラーの需要を高め、トラスツズマブ・バイオシミラー市場を促進しています。

トラスツズマブ・バイオシミラー市場の成長は、ヘルスケア支出の増加に大きく影響されると予想されます。ヘルスケア支出には、ヘルスケア商品およびサービスに費やされる総額が含まれ、これには個人のヘルスケア、公衆衛生活動、保健行政が含まれます。この支出は、トラスツズマブ・バイオシミラーの開発にとって極めて重要であり、製品を低コストで提供することを容易にするため、採用や開発が促進されます。ヘルスケア分野への投資が増加する中、バイオシミラー医薬品は生物学的製剤に代わるより安価な代替品を提供することで、患者の医療へのアクセスを向上させることができます。例えば、2024年5月、英国の政府機関である国家統計局の報告書によると、2022年から2023年にかけての総ヘルスケア支出は名目ベースで5.6%増加し、2022年の成長率はわずか0.9%でした。その結果、ヘルスケア支出の増加がトラスツズマブ・バイオシミラー市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界トラスツズマブ・バイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のトラスツズマブ・バイオシミラー市場：成長率分析
• 世界のトラスツズマブ・バイオシミラー市場の実績：規模と成長, 2019-2024
• 世界のトラスツズマブ・バイオシミラー市場の予測：規模と成長, 2024-2029, 2034F
• 世界トラスツズマブ・バイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のトラスツズマブ・バイオシミラー市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オギブリ
• ヘルズマ
• オントルザント
• トラジメラ
• その他の製品
• 世界のトラスツズマブ・バイオシミラー市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 補助乳がん
• 転移性乳がん
• 転移性胃がん
• その他の適応症
• 世界のトラスツズマブ・バイオシミラー市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局

第7章 地域別・国別分析

• 世界のトラスツズマブ・バイオシミラー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のトラスツズマブ・バイオシミラー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• トラスツズマブ・バイオシミラー市場：競合情勢
• トラスツズマブ・バイオシミラー市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Mylan NV Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Fujifilm Kyowa Kirin Biologics Co. Ltd.
• Innovent Biologics Inc.
• STADA Arzneimittel AG
• Apotex Inc.
• Samsung Bioepis Co. Ltd.
• Celltrion Inc.
• Zydus Lifesciences Limited
• BIOCAD
• Shanghai Henlius Biotech Inc.
• Biocon Limited
• Alvotech Holdings S.A.
• Polpharma Biologics S.A
• EirGenix Inc.
• Hetero Biopharma Limited
• Mabion SA

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• トラスツズマブ・バイオシミラー市場2029：新たな機会を提供する国
• トラスツズマブ・バイオシミラー市場2029：新たな機会を提供するセグメント
• トラスツズマブ・バイオシミラー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Trastuzumab biosimilars are therapeutic drugs targeting HER2 and specifically developed to treat both early and metastatic HER2-positive breast cancers. As a monoclonal antibody, trastuzumab biosimilar binds to the human epidermal growth factor receptor 2 (HER2)/neu receptor, thereby deactivating it.

The primary products in the trastuzumab biosimilars category include Ogivri, Herzuma, Ontruzant, Trazimera, and others. These biosimilars cater to various indications such as adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, among others. They are made available through distribution channels such as hospital pharmacies and online pharmacies.

The trastuzumab biosimilars market research report is one of a series of new reports from The Business Research Company that provides trastuzumab biosimilars market statistics, including trastuzumab biosimilars industry global market size, regional shares, competitors with a trastuzumab biosimilars market share, detailed trastuzumab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the trastuzumab biosimilars industry. This trastuzumab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The trastuzumab biosimilars market size has grown exponentially in recent years. It will grow from $4.27 billion in 2024 to $5.43 billion in 2025 at a compound annual growth rate (CAGR) of 27.1%. The growth in the historic period can be attributed to market expansion and global reach, patent expiry and market entry, rapid biosimilar development, clinical efficacy validation, competitive pricing.

The trastuzumab biosimilars market size is expected to see exponential growth in the next few years. It will grow to $14.69 billion in 2029 at a compound annual growth rate (CAGR) of 28.3%. The growth in the forecast period can be attributed to market competition intensification, biosimilar pipeline development, regulatory approvals and standardizations, global market penetration, physician adoption and prescribing patterns. Major trends in the forecast period include improved access, market segmentation strategies, educational campaigns, patient preference for biosimilars, physician acceptance.

The growth of the trastuzumab biosimilars market has been influenced by the increasing prevalence of breast and gastric cancer. Trastuzumab biosimilar is employed in treating breast cancer and metastatic gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression. For instance, in September 2023, the American Cancer Society reported that approximately 297,790 new cases of invasive breast cancer would be diagnosed in women, leading to about 43,700 women succumbing to breast cancer in the same year. Breast cancer is a prevalent type of cancer in India, constituting 14% of cancers in women. This rising prevalence of breast and gastric cancer enhances the demand for trastuzumab biosimilars due to cost-effectiveness compared to expensive medicines, thereby propelling the trastuzumab biosimilars market.

The growth of the trastuzumab biosimilars market is expected to be significantly influenced by rising healthcare expenditure. Healthcare expenditure encompasses the total amount spent on healthcare goods and services, which includes personal health care, public health activities, and health administration. This expenditure is crucial for the development of trastuzumab biosimilars as it facilitates the provision of these products at reduced costs, thereby promoting their adoption and development. As investments in the healthcare sector increase, biosimilars can enhance patient access to care by offering a more affordable alternative to biologics. For instance, in May 2024, a report from the Office for National Statistics, a UK-based government department, indicated that total healthcare expenditure rose by 5.6% in nominal terms between 2022 and 2023, compared to a growth rate of just 0.9% in 2022. Consequently, the rise in healthcare expenditure is driving the growth of the trastuzumab biosimilars market.

Key players in the trastuzumab biosimilars market are actively focused on launching new products in previously untapped regions, significantly influencing market dynamics. Companies within this sector are engaging in various strategic initiatives, including new product development, partnerships, and expansion of both geographic and product portfolios, to enhance their competitive edge and better meet customer needs. For example, in April 2024, Accord BioPharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), for treating several forms of HER2-overexpressing cancer. HERCESSI is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers are typically aggressive but respond well to targeted therapies. HERCESSI functions by binding to the HER2 receptor, inhibiting its activity and thereby slowing the replication of cancer cells.

Major companies operating in the trastuzumab biosimilars market are intensifying efforts to introduce novel products and secure approvals from government bodies to gain a competitive advantage. The drug launch signifies the introduction of a new pharmaceutical product, typically medication, into the commercial market for distribution and use. The drug approval process involves multiple stages, encompassing preclinical testing and clinical trials to assess the drug's effects. For instance, in February 2022, Samsung Bioepis Co. Ltd., a South Korea-based biopharmaceutical company, announced the approval of ONTRUZANT (also known as SB3) by Health Canada, a Canada-based government department. ONTRUZANT is a biosimilar referencing Herceptin (Trastuzumab) and is developed for treating adults with early breast cancer (EBC), metastatic breast cancer (MBC), and metastatic gastric cancer (MGC).

In March 2022, Biocon Biologics, a fully integrated biopharmaceutical company based in India, acquired Viatris Inc for $3.3 billion. This acquisition aims to establish a unique, fully integrated, global biosimilars enterprise. The strategic alliance combines the strengths and complementary skills of both entities, positioning Biocon Biologics for a decade of value creation for all stakeholders. Viatris Inc is a US-based pharmaceutical company and a developer of biosimilar trastuzumab.

Major companies operating in the trastuzumab biosimilars market include Pfizer Inc., Merck & Co., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Torrent Pharmaceuticals Limited

North America was the largest region in the trastuzumab biosimilars market in 2024. Middle East is expected to be the fastest growing region in the trastuzumab biosimilars market report during the forecast period. The regions covered in the trastuzumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the trastuzumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The trastuzumab biosimilars market consists of sales of herceptin, avastin, and Kanjinti. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Trastuzumab Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on trastuzumab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for trastuzumab biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trastuzumab biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Ogivri; Herzuma; Ontruzant; Trazimera; Other Products
• 2) By Indication: Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer; Other Indications
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy
• Companies Mentioned: Pfizer Inc.; Merck & Co.; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Mylan NV
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Trastuzumab Biosimilars Market Characteristics

3. Trastuzumab Biosimilars Market Trends And Strategies

4. Trastuzumab Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Trastuzumab Biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Trastuzumab Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Trastuzumab Biosimilars Market Growth Rate Analysis
• 5.4. Global Trastuzumab Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Trastuzumab Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Trastuzumab Biosimilars Total Addressable Market (TAM)

6. Trastuzumab Biosimilars Market Segmentation

• 6.1. Global Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ogivri
• Herzuma
• Ontruzant
• Trazimera
• Other Products
• 6.2. Global Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adjuvant Breast Cancer
• Metastatic Breast Cancer
• Metastatic Gastric Cancer
• Other Indications
• 6.3. Global Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy

7. Trastuzumab Biosimilars Market Regional And Country Analysis

• 7.1. Global Trastuzumab Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Trastuzumab Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Trastuzumab Biosimilars Market

• 8.1. Asia-Pacific Trastuzumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Trastuzumab Biosimilars Market

• 9.1. China Trastuzumab Biosimilars Market Overview
• 9.2. China Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Trastuzumab Biosimilars Market

• 10.1. India Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Trastuzumab Biosimilars Market

• 11.1. Japan Trastuzumab Biosimilars Market Overview
• 11.2. Japan Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Trastuzumab Biosimilars Market

• 12.1. Australia Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Trastuzumab Biosimilars Market

• 13.1. Indonesia Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Trastuzumab Biosimilars Market

• 14.1. South Korea Trastuzumab Biosimilars Market Overview
• 14.2. South Korea Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Trastuzumab Biosimilars Market

• 15.1. Western Europe Trastuzumab Biosimilars Market Overview
• 15.2. Western Europe Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Trastuzumab Biosimilars Market

• 16.1. UK Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Trastuzumab Biosimilars Market

• 17.1. Germany Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Trastuzumab Biosimilars Market

• 18.1. France Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Trastuzumab Biosimilars Market

• 19.1. Italy Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Trastuzumab Biosimilars Market

• 20.1. Spain Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Trastuzumab Biosimilars Market

• 21.1. Eastern Europe Trastuzumab Biosimilars Market Overview
• 21.2. Eastern Europe Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Trastuzumab Biosimilars Market

• 22.1. Russia Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Trastuzumab Biosimilars Market

• 23.1. North America Trastuzumab Biosimilars Market Overview
• 23.2. North America Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Trastuzumab Biosimilars Market

• 24.1. USA Trastuzumab Biosimilars Market Overview
• 24.2. USA Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Trastuzumab Biosimilars Market

• 25.1. Canada Trastuzumab Biosimilars Market Overview
• 25.2. Canada Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Trastuzumab Biosimilars Market

• 26.1. South America Trastuzumab Biosimilars Market Overview
• 26.2. South America Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Trastuzumab Biosimilars Market

• 27.1. Brazil Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Trastuzumab Biosimilars Market

• 28.1. Middle East Trastuzumab Biosimilars Market Overview
• 28.2. Middle East Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Trastuzumab Biosimilars Market

• 29.1. Africa Trastuzumab Biosimilars Market Overview
• 29.2. Africa Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Trastuzumab Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Trastuzumab Biosimilars Market Competitive Landscape
• 30.2. Trastuzumab Biosimilars Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Mylan NV Overview, Products and Services, Strategy and Financial Analysis

31. Trastuzumab Biosimilars Market Other Major And Innovative Companies

• 31.1. Fujifilm Kyowa Kirin Biologics Co. Ltd.
• 31.2. Innovent Biologics Inc.
• 31.3. STADA Arzneimittel AG
• 31.4. Apotex Inc.
• 31.5. Samsung Bioepis Co. Ltd.
• 31.6. Celltrion Inc.
• 31.7. Zydus Lifesciences Limited
• 31.8. BIOCAD
• 31.9. Shanghai Henlius Biotech Inc.
• 31.10. Biocon Limited
• 31.11. Alvotech Holdings S.A.
• 31.12. Polpharma Biologics S.A
• 31.13. EirGenix Inc.
• 31.14. Hetero Biopharma Limited
• 31.15. Mabion SA

32. Global Trastuzumab Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Trastuzumab Biosimilars Market

34. Recent Developments In The Trastuzumab Biosimilars Market

35. Trastuzumab Biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Trastuzumab Biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Trastuzumab Biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Trastuzumab Biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer